Harvard Bioscience, Inc.
HBIO
$6.04
$0.030.50%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 20.76M | 23.74M | 20.59M | 20.45M | 21.77M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 20.76M | 23.74M | 20.59M | 20.45M | 21.77M |
| Cost of Revenue | 8.51M | 9.56M | 8.57M | 8.92M | 9.59M |
| Gross Profit | 12.24M | 14.17M | 12.02M | 11.53M | 12.18M |
| SG&A Expenses | 10.04M | 7.81M | 8.79M | 8.80M | 10.16M |
| Depreciation & Amortization | 820.00K | 850.00K | 855.00K | 1.16M | 1.16M |
| Other Operating Expenses | -- | -- | -- | -- | 171.00K |
| Total Operating Expenses | 21.69M | 20.41M | 20.35M | 21.07M | 23.40M |
| Operating Income | -939.00K | 3.33M | 245.00K | -619.00K | -1.62M |
| Income Before Tax | -3.31M | -3.20M | -1.13M | -2.25M | -50.79M |
| Income Tax Expenses | 117.00K | -357.00K | 97.00K | 28.00K | -454.00K |
| Earnings from Continuing Operations | -3.42M | -2.85M | -1.23M | -2.28M | -50.34M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.42M | -2.85M | -1.23M | -2.28M | -50.34M |
| EBIT | -939.00K | 3.33M | 245.00K | -619.00K | -1.62M |
| EBITDA | 411.00K | 4.68M | 1.57M | 997.00K | 31.00K |
| EPS Basic | -0.77 | -0.64 | -0.28 | -0.52 | -11.42 |
| Normalized Basic EPS | -0.43 | -0.42 | -0.15 | -0.29 | -0.39 |
| EPS Diluted | -0.77 | -0.64 | -0.30 | -0.52 | -11.42 |
| Normalized Diluted EPS | -0.43 | -0.42 | -0.15 | -0.29 | -0.39 |
| Average Basic Shares Outstanding | 4.47M | 4.46M | 4.46M | 4.43M | 4.41M |
| Average Diluted Shares Outstanding | 4.47M | 4.46M | 4.46M | 4.43M | 4.41M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |